Project description DEENESFRITPL Helping surgeons to stop excessive bleeding In major surgery, excessive blood loss is associated with longer hospital stays, delayed recovery and increased mortality. Haemostatic agents can be used to control bleeding. However, most haemostats currently used by surgeons have lengthy preparation times, are difficult to apply and stick to surgical instruments limiting their suitable application. In this context, the EU-funded HEMOSNOW project will conduct the clinical study and upscale production to commercialise a unique haemostatic powder formulation capable of stopping minimum (oozing) and mild (pooling) bleeding (level 1 & 2 bleeding on the SPOTGRADE scale). It is a collagen-based powder that is ready to use and stops bleeding within 6 minutes. Show the project objective Hide the project objective Objective Excessive blood loss during surgery is a major concern - 42% of all patients who experience excessive blood loss during surgery die. Excessive bleeding contributes to longer hospital stays and delayed post-operative recovery. This incurs costs for both hospitals and patients with increased operating room time estimated to cost €1,542 - €2,554/hour while increased hospital stay is estimated at €1,038/day. Conventional techniques used to control excessive bleeding such as electrocautery are not always feasible and are often restricted to accessible vessels of a minimum size. This limits their applicability and contributes to postoperative drainage and pain. Haemostatic agents are formulations designed to arrest bleeding by supplementing the normal haemostatic mechanism of the body. Most haemostats currently used by surgeons to control bleeding have lengthy preparation times, are difficult to apply and stick to surgical instruments which limits their suitable application. In response, Biom’up has developed HEMOSNOW, a unique haemostatic powder formulation capable of stopping level 1 & 2 bleeding on the SPOTGRADE scale (developed and patented by Biom’up to quantitatively determine bleeding from surgical wounds). This collagen-based powder is ready to use and stops bleeding within 6minutes. It will equip surgeons with an effective tool for rapid and effective haemostasis, reduce operational procedure time and reduce the risk of surgical errors which occur when the surgeon’s vision is obscured by excessive blood. Patients benefit through lower healthcare costs, faster recovery and lower risks associated with blood transfusion. Biom’up is a French biotech company founded in 2005 which specialises in collagen-based resorbable medical devices for biosurgery. This project is expected to generate an accumulated revenue of €5 million in 5 years post commercialisation and employ 250 people. Fields of science social sciencessociologydemographymortalitymedical and health sciencesclinical medicinesurgerysocial sciencespolitical sciencespolitical transitionsrevolutions Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator BIOM'UP SA Net EU contribution € 50 000,00 Address 8, allee irene joliot curie 69800 Saint-priest France See on map Region Auvergne-Rhône-Alpes Rhône-Alpes Rhône Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00